PL356767A1 - Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding - Google Patents

Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding

Info

Publication number
PL356767A1
PL356767A1 PL00356767A PL35676700A PL356767A1 PL 356767 A1 PL356767 A1 PL 356767A1 PL 00356767 A PL00356767 A PL 00356767A PL 35676700 A PL35676700 A PL 35676700A PL 356767 A1 PL356767 A1 PL 356767A1
Authority
PL
Poland
Prior art keywords
useful
treatment
pharmaceutical composition
uterine bleeding
sex hormones
Prior art date
Application number
PL00356767A
Other languages
English (en)
Polish (pl)
Inventor
Yannis Tsounderos
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of PL356767A1 publication Critical patent/PL356767A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL00356767A 1999-03-31 2000-03-30 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding PL356767A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9904022A FR2791572A1 (fr) 1999-03-31 1999-03-31 Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables
PCT/FR2000/000790 WO2000059447A2 (fr) 1999-03-31 2000-03-30 Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables

Publications (1)

Publication Number Publication Date
PL356767A1 true PL356767A1 (en) 2004-07-12

Family

ID=9543854

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00356767A PL356767A1 (en) 1999-03-31 2000-03-30 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding

Country Status (16)

Country Link
EP (1) EP1143978A2 (fr)
JP (1) JP2002541076A (fr)
KR (1) KR20010102464A (fr)
CN (1) CN1346273A (fr)
AU (1) AU3662300A (fr)
BR (1) BR0008577A (fr)
CA (1) CA2361885A1 (fr)
EA (1) EA200100801A1 (fr)
FR (1) FR2791572A1 (fr)
HK (1) HK1044486A1 (fr)
HU (1) HUP0200244A3 (fr)
NO (1) NO20014022D0 (fr)
NZ (1) NZ513672A (fr)
PL (1) PL356767A1 (fr)
WO (1) WO2000059447A2 (fr)
ZA (1) ZA200106689B (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383993A (en) * 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
US5922699A (en) * 1996-06-07 1999-07-13 Pherin Corporation 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
BR9711812A (pt) * 1996-07-23 1999-08-24 Pherin Pharm Inc EsterÄides como estimuladores neuroqu¡micos do ÄrgÆo vomeronasal para aliviar os sintomas de pms e ansiedade

Also Published As

Publication number Publication date
EP1143978A2 (fr) 2001-10-17
KR20010102464A (ko) 2001-11-15
HUP0200244A2 (hu) 2002-07-29
NO20014022L (no) 2001-08-17
WO2000059447A2 (fr) 2000-10-12
CA2361885A1 (fr) 2000-10-12
HUP0200244A3 (en) 2003-05-28
JP2002541076A (ja) 2002-12-03
NO20014022D0 (no) 2001-08-17
HK1044486A1 (zh) 2002-10-25
NZ513672A (en) 2001-09-28
EA200100801A1 (ru) 2002-04-25
AU3662300A (en) 2000-10-23
CN1346273A (zh) 2002-04-24
FR2791572A1 (fr) 2000-10-06
ZA200106689B (en) 2002-11-14
BR0008577A (pt) 2002-10-01
WO2000059447A3 (fr) 2001-04-26

Similar Documents

Publication Publication Date Title
HUP0103494A2 (en) Process for intermittent administration use of growth hormone secretagogues for the manufacture of pharmaceutical compositions for intermittent administration and kit comprising thereof
PT2450043T (pt) Composição farmacêutica para uso dérmico no tratamento de psoríase compreendendo calcipotriol e betametasona
HUP0301212A3 (en) Use of glucagon-like peptide-1 analogs for preparation pharmaceutical compositions and for treating diabetes
HK1005985A1 (en) Combined use of hyaluronic acid and therapeutic agents to improve the therapeutic effect
HU0103558D0 (en) Pharmaceutical composition for the treatment of stroke and traumatic brain insury
EP1404343A4 (fr) Combinaisons therapeutiques pour le traitement des carences hormonales
MY136952A (en) Aqueous sustained-release formulations of proteins
GB0013378D0 (en) Use of therapeutic benzamide derivatives
HK1149719A1 (en) Ciclesonide contained pharmaceutical composition for application to mucosa
HUP0301244A3 (en) Use of rapamycin for preparation of pharmaceutical composition to treat heart and cardiovascular diseases
HUP0301460A3 (en) Use of antiprogestins for producing pharmaceutical compositions for prohylaxis and treatment of hormone-dependent diseases
AU2002339991A1 (en) Use of hif-1alpha variants to accelerate wound healing
IL156139A0 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
AU6788701A (en) Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
GB9912639D0 (en) Improvements in and relating to treatment of respiratory conditions
NZ513672A (en) Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
GB0312566D0 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
HUP0102696A3 (en) Use of growth hormone secretagogues for the preparation of pharmaceutical compositions stimulating or increasing appetite
IL150122A0 (en) Remedies for external use for allergic skin diseases
AU6985900A (en) Use of n-acetyl-cysteine in the manufacture of topical pharmaceutical compositions for the treatment of allergic pathologies of the respiratory tract
IL131355A0 (en) Use of pivagabin to prepare pharmaceutical compositions
HUP0201875A3 (en) Use of antiprogestagens for preparing pharmaceutical compositions for contraception in combined therapy
ATA171599A (de) Pharmazeutische zusammensetzung zur abdeckung des grundbedarfs an vitaminen
HUP0402139A3 (en) 17 alpha-hydroxy-14 betha-steroids with hormonal effect and their use for preparation of pharmaceutical compositions
PL385375A3 (pl) Nowe związki, pochodne pirydyny, zawierająca je kompozycja oraz ich farmaceutyczne zastosowanie w powikłaniach układu naczyniowego cukrzycy i związanych z wiekiem

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)